Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada.
Breast. 2010 Dec;19(6):545-8. doi: 10.1016/j.breast.2010.06.003. Epub 2010 Jul 7.
At present, there is no gold standard test for the investigation of ovarian function in pre-menopausal breast cancer patients who develop amenorrhea after chemotherapy. Clinical, biochemical and biophysical investigations continue to be utilized in clinical practice, despite concerns regarding their predictive value for menopause. The resulting uncertainty about a woman's actual menopausal status has important consequences for patient management. These include choice of appropriate endocrine therapy, assessment of residual ovarian function and its effect on breast cancer recurrence, fertility issues and the prediction of the likelihood of conception. It is hoped that the development of novel surrogates may allow clinicians to more accurately assess menopausal status and thereby facilitate tailored and individualised therapy for this common group of patients.
目前，对于化疗后出现闭经的绝经前乳腺癌患者，卵巢功能的检查尚无金标准测试。尽管对其预测绝经的价值存在担忧，但临床、生化和生物物理检查仍在临床实践中得到应用。女性实际绝经状态的不确定性对患者管理具有重要影响。这些影响包括选择合适的内分泌治疗、评估残留卵巢功能及其对乳腺癌复发的影响、生育问题以及预测受孕的可能性。人们希望新型替代物的开发可以使临床医生更准确地评估绝经状态，从而为这一常见患者群体提供更具针对性和个体化的治疗。
